Conduit Pharmaceuticals Stock Market Value
| CDTTW Stock | 0.02 0 29.03% |
| Symbol | Conduit |
Conduit Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Conduit Pharmaceuticals. If investors know Conduit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Conduit Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (3.22) |
The market value of Conduit Pharmaceuticals is measured differently than its book value, which is the value of Conduit that is recorded on the company's balance sheet. Investors also form their own opinion of Conduit Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Conduit Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Conduit Pharmaceuticals' market value can be influenced by many factors that don't directly affect Conduit Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Conduit Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Conduit Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Conduit Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Conduit Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Conduit Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Conduit Pharmaceuticals.
| 12/13/2022 |
| 12/02/2024 |
If you would invest 0.00 in Conduit Pharmaceuticals on December 13, 2022 and sell it all today you would earn a total of 0.00 from holding Conduit Pharmaceuticals or generate 0.0% return on investment in Conduit Pharmaceuticals over 720 days. Conduit Pharmaceuticals is related to or competes with DiaMedica Therapeutics, Lyra Therapeutics, and Centessa Pharmaceuticals. Conduit Pharmaceuticals is entity of United States More
Conduit Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Conduit Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Conduit Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 25.12 | |||
| Information Ratio | 0.1138 | |||
| Maximum Drawdown | 157.5 | |||
| Value At Risk | (40.88) | |||
| Potential Upside | 73.08 |
Conduit Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Conduit Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Conduit Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Conduit Pharmaceuticals historical prices to predict the future Conduit Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0998 | |||
| Jensen Alpha | 2.62 | |||
| Total Risk Alpha | (1.72) | |||
| Sortino Ratio | 0.1576 | |||
| Treynor Ratio | 0.3567 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Conduit Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Conduit Pharmaceuticals Backtested Returns
Conduit Pharmaceuticals is out of control given 3 months investment horizon. Conduit Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.19, which signifies that the company had a 0.19% return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 5.04% are justified by taking the suggested risk. Use Conduit Pharmaceuticals Risk Adjusted Performance of 0.0998, downside deviation of 25.12, and Mean Deviation of 26.29 to evaluate company specific risk that cannot be diversified away. Conduit Pharmaceuticals holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 11.45, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform. Use Conduit Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Conduit Pharmaceuticals.
Auto-correlation | 0.21 |
Weak predictability
Conduit Pharmaceuticals has weak predictability. Overlapping area represents the amount of predictability between Conduit Pharmaceuticals time series from 13th of December 2022 to 8th of December 2023 and 8th of December 2023 to 2nd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Conduit Pharmaceuticals price movement. The serial correlation of 0.21 indicates that over 21.0% of current Conduit Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.21 | |
| Spearman Rank Test | -0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Conduit Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Conduit Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Conduit Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Conduit Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Conduit Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Conduit Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Conduit Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Conduit Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Conduit Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Conduit Pharmaceuticals Lagged Returns
When evaluating Conduit Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Conduit Pharmaceuticals stock have on its future price. Conduit Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Conduit Pharmaceuticals autocorrelation shows the relationship between Conduit Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Conduit Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.